Simeticone

Summary

Simeticone (CHEMBL2108741) is a phase-3 clinical-stage unknown; indicated across 1 condition including constipation disorder.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 1 condition
• Clinical trials: 5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108741
Name	Simeticone
Type	Unknown
Max phase	3

Also known as: Asilone windcheaters, Infacol, Phazyme, Simeticona, Simeticone, Wind-eze, Windsetlers, SIMETICONE

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
constipation disorder	3	MONDO:0002203	HP:0002019

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE4	3
PHASE3	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00542295	PHASE4	COMPLETED	Efficacy and Safety of Meteospasmyl® in Irritable Bowel Syndrome
NCT01404923	PHASE4	COMPLETED	Effectiveness of On-demand Meteospasmyl® Use in Irritable Bowel Syndrome (IBS)
NCT06367452	PHASE4	COMPLETED	Exploratory Pilot Study to Evaluate the Pharmacokinetic Profile of Magaldrate
NCT02211976	PHASE3	COMPLETED	Efficacy and Tolerability of Bisacodyl Sugar Coated Tablets, Simeticone Chewing Tablets and Their Combination in Constipation and Bloatedness
NCT07293234	Not specified	NOT_YET_RECRUITING	Effect of Simethicone on Helicobacter Pylori Detection in Routine Endoscopy

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).